New Developments in the Medical Management of Prostate Cancer

Kohli, Manish; Tindall, Donald J.
January 2010
Mayo Clinic Proceedings;Jan2010, Vol. 85 Issue 1, p77
Academic Journal
Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.


Related Articles

  • Hormonal therapies for PCa yield similar outcomes. Tennant, Scott // Urology Times;Feb2002, Vol. 30 Issue 2, p22 

    Reports the relationship between the outcomes of primary hormonal therapy and endocrine-related quality-of-life for prostate cancer treatment in Bethesda, Maryland. Inference to the data from the National Cancer Institute; Similarity of sexual function outcomes among orchiectomy patients;...

  • Concurrent palliative care reduced symptom burden in prostate cancer.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p22 

    The article reports on the improved outcomes produced by symptom co-management delivered with oncologic or surgical care for men with prostate cancer, which is based on a study presented at the annual assembly of the American Academy of Hospice and Palliative Medicine (AAHPM) in the U.S. in 2011.

  • Minerva.  // BMJ: British Medical Journal (International Edition);10/10/98, Vol. 317 Issue 7164, p1024 

    Presents news items pertaining to health in Great Britain. Explanation on why outpatients fail to keep clinic appointments according to an article in the `International Journal of Clinical Practice'; Effects of PC-SPES in patients with prostate cancer; Suggestion for melting fat free cheese;...

  • Degarelix not good value for money for the UK NHS.  // PharmacoEconomics & Outcomes News;9/17/2011, Issue 637, p7 

    The article reports on a study, published in the "British Journal of Urology," which revealed that degarelix may not be cost-effective in comparison to triptorelin and antiandrogen therapy for treating patients with advanced hormone-dependent prostate cancer in Great Britain.

  • Impact of new technology on costs for prostate cancer.  // PharmacoEconomics & Outcomes News;4/2/2011, Issue 625, p6 

    The article discusses research on the utilization and cost of surgical and radiation treatments for prostate cancer, by P. L. Nguyen and colleagues, published in the "Journal of Clinical Oncology."

  • Health Committee prostate cancer recommendations find favour with the Government.  // New Zealand Doctor;8/10/2011, p27 

    The article reports that the New Zealand government will probably quickly implement majority of the Health Committee's recommendations to improve the early detection and treatment of prostate cancer. According to the author, the Health Committee is also calling for the establishment of a quality...

  • CME Questions.  // Clinical Oncology Alert;Aug2008, Vol. 24 Issue 8, p63 

    A quiz concerning medical treatments and information about breast and prostate cancer is presented.

  • Health-related quality of life in men with prostate cancer. Litwin, M S; Penson, D F // Prostate Cancer & Prostatic Diseases;1998, Vol. 1 Issue 5, p228 

    Focuses on the task of maintaining and improving health related quality of life (HRQOL) in the management of prostate cancer. Principal challenge of assessing HRQOL; Established instruments for HRQOL; Discussion on the prostate-specific domains of HRQOL.

  • Proven Best Choice guides by Families USA and ICER.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 745 Issue 1, p5 

    The article focuses on the Proven Best Choice guides published by the non-profits Families USA and Institute for Clinical and Economic Review (ICER) of the U.S., on healthcare options for U.S. people including treatment for low-risk prostate cancer and screening of women with dense breast tissue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics